Business Description
Rhelion Life Sciences Corp
NAICS : 312310
SIC : 182
ISIN : CA75671E1097
Share Class Description:
STU:4YX0: Ordinary SharesCompare
Compare
Traded in other countries / regions
RHEL.CanadaTRUFF.USA4YX0.Germany IPO Date
2020-12-17Description
Rhelion Life Sciences Corp is a pharmaceutical research and development company focused on natural psychedelic medicines for psychiatric and neurological conditions. The company is engaged in the discovery and development of drug candidates derived from naturally occurring psychoactive compounds, targeting indications such as depression, anxiety, post-traumatic stress disorder, and other mental health disorders. Its activities center on preclinical and clinical research, formulation development, and regulatory pathways for psychedelic-based therapeutics. As a development-stage company, Rhelion does not yet market approved products and relies on equity financing, grants, and partnership arrangements to fund its research programs. Its primary market is the United States, with potential expansion into other jurisdictions where regulatory frameworks permit psychedelic-assisted therapy research and commercialization. The company operates in the emerging psychedelic medicine sector, competing with other biopharmaceutical firms pursuing synthetic and natural psychedelic compounds.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.62 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.2 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.66 | |||||
Beneish M-Score | 1 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.1 | |||||
3-Year EBITDA Growth Rate | -4.6 | |||||
3-Year FCF Growth Rate | 19.1 | |||||
3-Year Book Growth Rate | -25.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 9.49 | |||||
9-Day RSI | 17.21 | |||||
14-Day RSI | 22.87 | |||||
3-1 Month Momentum % | -36.36 | |||||
6-1 Month Momentum % | -30 | |||||
12-1 Month Momentum % | -38.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.25 | |||||
Quick Ratio | 3.14 | |||||
Cash Ratio | 2.39 | |||||
Days Inventory | 174.11 | |||||
Days Sales Outstanding | 62.5 | |||||
Days Payable | 194.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | 1.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 42.66 | |||||
Operating Margin % | -142.31 | |||||
Net Margin % | -225.36 | |||||
EBITDA Margin % | -233.28 | |||||
FCF Margin % | -94.69 | |||||
OCF Margin % | -94.53 | |||||
ROE % | -44.57 | |||||
ROA % | -37 | |||||
ROIC % | -59.02 | |||||
3-Year ROIIC % | -13.12 | |||||
ROC (Joel Greenblatt) % | -161.41 | |||||
ROCE % | -48.17 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 3.09 | |||||
PEG Ratio | 0.88 | |||||
PS Ratio | 1.33 | |||||
PB Ratio | 0.3 | |||||
EV-to-EBIT | -1.46 | |||||
EV-to-EBITDA | -1.53 | |||||
EV-to-Revenue | 3.58 | |||||
EV-to-FCF | -3.13 | |||||
Price-to-GF-Value | 0.01 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.01 | |||||
Earnings Yield (Greenblatt) % | -68.63 | |||||
FCF Yield % | -21.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rhelion Life Sciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.909 | ||
| EPS (TTM) (€) | -0.009 | ||
| Beta | -2.4873 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 1.54 | ||
| Volatility % | 355.1 | ||
| 14-Day RSI | 22.87 | ||
| 14-Day ATR (€) | 0.003103 | ||
| 20-Day SMA (€) | 0.011705 | ||
| 12-1 Month Momentum % | -38.6 | ||
| 52-Week Range (€) | 0.0002 - 0.0266 | ||
| Shares Outstanding (Mil) | 614.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rhelion Life Sciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rhelion Life Sciences Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rhelion Life Sciences Corp Frequently Asked Questions
What is Rhelion Life Sciences Corp(STU:4YX0)'s stock price today?
The current price of STU:4YX0 is €0.00. The 52 week high of STU:4YX0 is €0.03 and 52 week low is €0.00.
When is next earnings date of Rhelion Life Sciences Corp(STU:4YX0)?
The next earnings date of Rhelion Life Sciences Corp(STU:4YX0) is .
Does Rhelion Life Sciences Corp(STU:4YX0) pay dividends? If so, how much?
Rhelion Life Sciences Corp(STU:4YX0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers